Not that far away..Dec 6/7, breast cancer symposium Onc/ et. al. Will be presenting at the San Antonio global breast cancer symposium with 2 abstracts.
both have embargoed information " to be released day of presentation ".
One, being the very long awaited conclusion of the Aware-1, biomarker data.
second being a report from A.N. Run-in trial.
both o& which are key in progressing into phase 3;MBC
These are straight up facts.
I find it interesting, that in face of this N.R. & updates from the analysts, all being " more positive".
That we have a handful of doom & gloom posters on here.
absolutly freedom of speech. Say what you want.
However? Motives of random non- sense about R/ S , folding etc etc.
My " speculation" oF a partnership & soon, is met with consensus from the 3 resent analysts reports.
In vague terms all say the same thing.
Near the end of this year, all required data will be revealed & it is business development time.
back to panc cancer results?
should the numbers keep moving forward...it does add value to the potential partnership with Roche.
The lowest analyst target Is $6/ps. Highest is $15ps.
relax & wait.